11 completed, 2 terminated, 2 unknown, 2 withdrawn. 6 Phase 4, 3 Phase 2, 2 Not applicable, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow elvitegravir: new trials by email Literature Review of elvitegravir trials Research Report on elvitegravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Analysis of Crushed and Whole Tablet Genvoya Genvoya Oral dose, Genvoya Crushed Dose - Healthy Volunteers | Phase 4 | Completed | Johns Hopkins University | 12 | 2019-04-15 | 2023-01-31 |
| Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir - HIV | Terminated | Fondation Ophtalmologique Adolphe de Rothschild | 1 | 2018-11-19 | 2020-02-27 | |
| Same-Day Treatment With Genvoya vs. EFV/TDF/3TC Elvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC - HIV/AIDS | Not applicable | Withdrawn | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | 2018-05-01 | 2020-03-18 | |
| Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection Elvitegravir/Cobicistat/Emtricitabine - Chronic Hepatitis B in HIV Patient, Kidney Injury | Unknown | National Taiwan University Hospital | 275 | 2018-02-06 | 2019-08-28 | |
| Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy Genvoya, Epclusa, Biktarvy - HIV-1-infection, Hepatitis C, Chronic | Phase 4 | Unknown | Saskatchewan Health Authority - Regina Area | 25 | 2018-02-01 | 2019-12-24 |
| Early ART to Limit Infection and Establishment of Reservoir elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 195 | 2017-01-24 | 2025-08-29 |
| Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra), elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil - HIV | Phase 4 | Completed | Fundacion Clinic per a la Recerca Biomédica | 160 | 2015-06-06 | 2017-02-23 |
| Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC, Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC, Darunavir - Healthy | Phase 1 | Completed | Janssen Sciences Ireland UC | 72 | 2015-06-01 | 2017-10-17 |
| Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive elvitegravir/cobicistat/emtricitabine/tenofovir, Darunavir, abacavir/lamivudine - Patient Compliance, Antiretroviral Therapy Intolerance | Phase 4 | Withdrawn | Juan A. Arnaiz | 2015-06-01 | 2025-07-30 | |
| Renal Integrase Study Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) - HIV | Phase 4 | Completed | St Stephens Aids Trust | 60 | 2015-03-01 | 2017-06-27 |
| SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers Dolutegravir, Elvitegravir and Cobicistat - HIV | Phase 1 | Completed | St Stephens Aids Trust | 17 | 2014-10-01 | 2016-08-15 |
| An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks - HIV-2 Infection | Phase 4 | Completed | University of Washington | 30 | 2014-09-01 | 2018-07-26 |
| Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) - HIV Disease | Not applicable | Completed | Massachusetts General Hospital | 10 | 2014-01-01 | 2017-07-28 |
| Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants EVG, Background regimen - Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 31 | 2013-08-26 | 2018-08-09 |
| Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir Elvitegravir, Raltegravir, EVG placebo - HIV Infection | Phase 3 | Completed | Gilead Sciences | 724 | 2008-07-01 | 2016-05-30 |
| Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection EVG, RTV, ARV regimen - HIV Infections | Phase 2 | Completed | Gilead Sciences | 192 | 2007-02-01 | 2016-04-25 |
| Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2 - HIV Infections | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1578 | 2003-06-09 | 2025-12-02 |
Acquired Immunodeficiency Syndrome (6) · HIV Infections (4) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Coinfection (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Opioid-Related Disorders (1) · Patient Compliance (1)
Gilead Sciences (3) · St Stephens Aids Trust (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Fundacion Clinic per a la Recerca Biomédica (1) · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic (1) · Janssen Sciences Ireland UC (1) · Johns Hopkins University (1) · Juan A. Arnaiz (1) · Massachusetts General Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Taiwan University Hospital (1) · Saskatchewan Health Authority - Regina Area (1) · Shanxi Bethune Hospital (1) · University of Washington (1)
United States (7) · Puerto Rico (3) · Spain (3) · Thailand (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Canada (2) · France (2) · Italy (2) · South Africa (2) · Argentina (1) · Australia (1) · Botswana (1) · Germany (1)
Alexander Wong, MD (1) · Chien-Ching Hung (1) · Craig Hendrix, MD (1) · Geoffrey S Gottlieb, MD PhD (1) · Graeme Moyle, MD, MBBS, Dip GUN (1) · Javier Szwarcberg, MD, MPH (1) · Jean W Pape, MD (1) · Mark Mirochnick, MD (1) · Martin Rhee, MD (1) · Moussa Seydi, MD (1)
PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 20002783, PMID 20632458, PMID 21283017, PMID 22015077, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 29672676, PMID 30134297, PMID 30358179, PMID 30412360, PMID 30530925, PMID 30715324, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33273214, PMID 33318014, PMID 33382405, PMID 33540057, PMID 34076612, PMID 34732682, PMID 36301928, PMID 40741959, PMID 42828638
2014 (1), 2015 (1), 2UM1AI068636 (1)